Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2024

Genmab — Februar 2024

Planlagt Fastgjort Låst Flyttet Genmab
1.6k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • StockBullS Offline
    StockBullS Offline
    StockBull
    wrote on sidst redigeret af
    #167

    Godmorgen 🙂 @w, der er jo stille periode nu 14 dage før regnskabet så begrænset hvad svar man kan forvente. Men enig i Biotech er high risk i.f.t at investere i ETFer, index m.m. Men hvis alt går godt kan Genmab da sikkert slå SP500 index på den lange bane. Det har Genmab jo faktisk gjort hvis vi ser bort fra de sidste 2 år hvor den tabte voldgift og de høje renter vel er skyld i tab på ca. 1000 kurs point.

    1 Reply Last reply
    0
    • StockBullS Offline
      StockBullS Offline
      StockBull
      wrote on sidst redigeret af
      #168

      Men der er vel en rationel bund et eller andet sted her omkring de 1900 i genmab og p.t ser sp500 faktisk lidt overvurderet ud.

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Stroka
        wrote on sidst redigeret af
        #169

        God morgen 🙂

        1 Reply Last reply
        0
        • StockBullS Offline
          StockBullS Offline
          StockBull
          wrote on sidst redigeret af
          #170

          Feb 14, 2024 kommer regnskab og 2024 guiding som vil give svar på fremtidige udgifter. Typisk 32-35% af omsætningen går til udgifter

          1 Reply Last reply
          0
          • StockBullS Offline
            StockBullS Offline
            StockBull
            wrote on sidst redigeret af
            #171

            60-70% går til udgifter inklusiv skat, lønninger, R/D

            1 Reply Last reply
            0
            • StockBullS Offline
              StockBullS Offline
              StockBull
              wrote on sidst redigeret af
              #172

              Average profit: (31.5% of cumulative revenue) -- of industry average

              1 Reply Last reply
              0
              • StockBullS Offline
                StockBullS Offline
                StockBull
                wrote on sidst redigeret af
                #173

                Link Preview Image
                The Average Profit Margin of Pharmaceuticals | Bizfluent

                The pharmaceutical industry has some of the highest profit margins in the world, up to 45 percent for some of the largest companies in big pharma.

                favicon

                Bizfluent (bizfluent.com)

                1 Reply Last reply
                0
                • StockBullS Offline
                  StockBullS Offline
                  StockBull
                  wrote on sidst redigeret af
                  #174

                  Genmab har egentlig ok profit margin. PE har nok bare været kørt for højt op f.eks i 2022 var PE omkring 70. Nu er PE mere rimlig i.f.t profit. Alt bliver godt igen hvis JNJ opter in på cd38 - så vil PE blæse op over 40 igen

                  1 Reply Last reply
                  0
                  • StockBullS Offline
                    StockBullS Offline
                    StockBull
                    wrote on sidst redigeret af
                    #175

                    Correction - det var 2021 PE var over 70

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bibob
                      wrote on sidst redigeret af
                      #176

                      God morgen 🙂

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        LP90
                        wrote on sidst redigeret af
                        #177

                        God morgen 🙂

                        1 Reply Last reply
                        0
                        • J Offline
                          J Offline
                          JKY_VH
                          wrote on sidst redigeret af
                          #178

                          god morgen og velkommen tilbage fra ferie SB 😉

                          1 Reply Last reply
                          0
                          • StockBullS Offline
                            StockBullS Offline
                            StockBull
                            wrote on sidst redigeret af
                            #179

                            mange tak jky. Jeg er nu stadig på ferie men lidt skal der arbejdes selv i ferien. Som fuldtids investor bestemmer man selv tempo og arbejdstimer per uge. Gik på selvbetalt pension i 2020.

                            1 Reply Last reply
                            0
                            • J Offline
                              J Offline
                              JKY_VH
                              wrote on sidst redigeret af
                              #180

                              Fedt og fortsat god ferie;-)

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #181

                                Epcoritamab on the EMA PRAC agenda, Scope: Extension of indication to include treatment of adult patients with relapsed or
                                refractory (R/R) follicular lymphoma (FL) after two or more lines https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-5-8-february-2024_en.pdf

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #182

                                  BOFA sees a peak sales for Kesimpta of $5.7bn vs cons $5.1bn https://twitter.com/semodough/status/1754694000307494971

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #183

                                    It seems like we need to get guidance out of the way before fokus will be on data and alike

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #184

                                      could well be. not easy to estimate this guidance either, not so sure what to expect from the cost side. Actually their first Darzalex guidance last year was quite good in hindsight, with a mid point of 9.7bn

                                      1 Reply Last reply
                                      0
                                      • JørgenVarnæsJ Offline
                                        JørgenVarnæsJ Offline
                                        JørgenVarnæs
                                        wrote on sidst redigeret af
                                        #185

                                        I'm looking for a more direct connection between development cost and clinical effect - till now a lot of money has been thrown at early stage programs with no visible effect. This has forced analysts to consider development initiatives as pure loss-giving activities - maybe this is why Genmab is considered a cost sinkhole by the market...?

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #186

                                          what do you expect from them then, concretely? because the only way i can imagine them proving this to you is to grind through these early stage programs into maturity and hopefully approval. i don't know how else they can do this? isn't that what biotech is all about?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper